M. Bissery

发表

RPR 130401, a Nonpeptidomimetic Farnesyltransferase Inhibitor with in Vivo Activity

P. Vrignaud, P. Mailliet, F. Lavelle, 1999, Annals of the New York Academy of Sciences.

Preclinical evaluation of TXD258, a new taxoid

P. Vrignaud, J. Riou, H. Bouchard, 2000 .

Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel

P. Vrignaud, S. Sidhu, M. Bissery, 2013, Cancer Chemotherapy and Pharmacology.

Synthesis and antitumor activity of 1-[[(dialkylamino)alkyl]amino]-4-methyl-5H-pyrido[4,3-b]benzo[e]- and -benzo[g])indoles. A new class of antineoplastic agents.

C. Nguyen, E. Bisagni, F. Lavelle, 1990, Journal of medicinal chemistry.

Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities.

C. Nguyen, A. Larsen, J. Riou, 1993, Cancer research.

Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.

C. Paoletti, F. Lavelle, S. Giorgi-Renault, 1991, Journal of medicinal chemistry.

Synthesis and structure-activity relationships of new antitumor taxoids. Effects of cyclohexyl substitution at the C-3' and/or C-2 of taxotere (docetaxel).

P. Vrignaud, J. Riou, I. Ojima, 1994, Journal of medicinal chemistry.

Synthesis and biological evaluation of amino-substituted benzo[f]pyrido[4,3-b] and pyrido[3,4-b]quinoxalines: a new class of antineoplastic agents.

P. Vrignaud, C. Nguyen, J. Riou, 1995, Anti-cancer drug design.

Further SAR in the new antitumor 1-amino-substituted gamma-carbolines and 5H-benzo[e]pyrido[4,3-b]indoles series.

C. Nguyen, J. Riou, E. Bisagni, 1992, Anti-cancer drug design.

Synthesis and antitumor properties of new 4-methyl-substituted- pyrido[4,3-b]indoles (gamma-carbolines).

C. Nguyen, E. Bisagni, F. Lavelle, 1992, Anti-cancer drug design.

Preclinical evaluation of docetaxel (Taxotere).

P. Vrignaud, M. Bissery, J. Riou, 1995, Seminars in oncology.

In vivo evaluation of the lrinotecan-oxaliplatin comblnation

P. Vrignaud, M. Bissery, 1997 .

Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice

P. Vrignaud, M. Bissery, G. Chabot, 1996, Anti-cancer drugs.

Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience.

M. Bissery, G. Nohynek, G. Sanderink, 1995, Anti-cancer drugs.